Which novel agents for acute myeloid leukemia are likely to change practice?

There has been little progress in drug development in acute myeloid leukemia (AML) in the recent past. This recently changed with the approval of several therapies for patients with this disease and prompts one to consider which therapies may change practice for patients with AML. To change practice, a therapy must be adopted as a standard of care intervention based on its efficacy and safety profile and must endure as the accepted treatment for a particular indication for a significant period of time. Here I attempt to determine which therapies, approved or in development, may change practice in the field of AML.